Straits Times Index
3,319.90 +12.00 (+0.36%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,895.95 -299.65 (-1.56%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,463.21 -432.80 (-0.62%) CMC Crypto 200
1,510.55 +7.89 (+0.52%)
Valneva SE (INRLF)
| Previous close | 4.5000 |
| Open | 4.3280 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.3280 - 4.3280 |
| 52-week range | 3.3500 - 8.5500 |
| Volume | |
| Avg. volume | 1,233 |
| Market cap | 602.254M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireValneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva’s pre-clinical
- GlobeNewswire
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) aft
- GlobeNewswire
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance Cash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV)1. Significantly extended cash runway with recent update of debt financing agreement2Substantially lower cash burn expected in 2024 as Valneva expects to complete its cost contribu
